The estimated Net Worth of Zachary B. Fleming is at least $1.75 Milion dollars as of 8 November 2022. Mr Fleming owns over 417 units of Sanara MedTech stock worth over $1,215,408 and over the last 5 years he sold SMTI stock worth over $188,025. In addition, he makes $345,410 as Chief Exec. Officer at Sanara MedTech.
Mr has made over 9 trades of the Sanara MedTech stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 417 units of SMTI stock worth $13,761 on 8 November 2022.
The largest trade he's ever made was selling 1,680 units of Sanara MedTech stock on 5 July 2022 worth over $37,565. On average, Mr trades about 260 units every 16 days since 2020. As of 8 November 2022 he still owns at least 36,270 units of Sanara MedTech stock.
You can see the complete history of Mr Fleming stock trades at the bottom of the page.
Zachary B. Fleming is the Chief Exec. Officer at Sanara MedTech.
As the Chief Exec. Officer of Sanara MedTech, the total compensation of Mr Fleming at Sanara MedTech is $345,410. There are no executives at Sanara MedTech getting paid more.
Mr Fleming is 46, he's been the Chief Exec. Officer of Sanara MedTech since . There are 7 older and no younger executives at Sanara MedTech. The oldest executive at Sanara MedTech Inc. is Cathy Bradshaw, 67, who is the Pres of Wound Care Innovations LLC.
Zachary's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $134,660 worth of Sanara MedTech stock and bought 963,856 units worth $8,000,005 . The most active insiders traders include Ronald T Nixon, James W Stuckert oraz Zachary B. Fleming. On average, Sanara MedTech executives and independent directors trade stock every 148 days with the average trade being worth of $6,486,564. The most recent stock trade was executed by Zachary B. Fleming on 26 October 2021, trading 1,000 units of SMTI stock currently worth $34,040.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: